Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aimovog

- PMLiVE

Novartis restructures organisation to support growth and innovation

The new operational structure will involve integrating pharmaceuticals and oncology business units into an Innovative Medicines business

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients

There are an estimated 130,000 people with MS in the UK

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

The licence option agreement is for next-generation gene therapy vectors for neurological diseases

- PMLiVE

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

Lung cancer is recorded as being the third most common cancer, with an estimated 48,000 new cases diagnosed in the UK every year

- PMLiVE

Amgen’s Lumakras shows promising results for patients with advanced pancreatic cancer

The results from the phase 1/2 trial showed encouraging and clinically meaningful anticancer activity in patients with the KRAS G12C-mutation

- PMLiVE

Amgen and Plexium announce new research collaboration worth over $500m

The two companies will work to identify and develop new treatments for cancer and other serious diseases

- PMLiVE

Amgen’s Lumykras receives conditional marketing authorisation from EC

The drug is the first targeted therapy for patients diagnosed with advanced NSCLC with the KRAS G12C mutation

- PMLiVE

Novartis to pay up to $1.5bn for Gyroscope

The acquisition of ocular gene therapy company, Gyroscope, adds GT005 to the Novartis portfolio – a one-time gene therapy for geographic atrophy, a leading cause of blindness

- PMLiVE

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis is to pay $300m upfront to BeiGene in a multifaceted deal to enhance its oncology portfolio and expand coverage of the Chinese market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links